These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 37717945)
1. A marginalized two-part joint model for a longitudinal biomarker and a terminal event with application to advanced head and neck cancers. Rustand D; Briollais L; Rondeau V Pharm Stat; 2024; 23(1):60-80. PubMed ID: 37717945 [TBL] [Abstract][Full Text] [Related]
2. Two-part joint model for a longitudinal semicontinuous marker and a terminal event with application to metastatic colorectal cancer data. Rustand D; Briollais L; Tournigand C; Rondeau V Biostatistics; 2022 Jan; 23(1):50-68. PubMed ID: 32282877 [TBL] [Abstract][Full Text] [Related]
3. Bayesian estimation of two-part joint models for a longitudinal semicontinuous biomarker and a terminal event with INLA: Interests for cancer clinical trial evaluation. Rustand D; van Niekerk J; Rue H; Tournigand C; Rondeau V; Briollais L Biom J; 2023 Apr; 65(4):e2100322. PubMed ID: 36846925 [TBL] [Abstract][Full Text] [Related]
4. Analysis of longitudinal semicontinuous data using marginalized two-part model. Jaffa MA; Gebregziabher M; Garrett SM; Luttrell DK; Lipson KE; Luttrell LM; Jaffa AA J Transl Med; 2018 Nov; 16(1):301. PubMed ID: 30400798 [TBL] [Abstract][Full Text] [Related]
5. Shared parameter and copula models for analysis of semicontinuous longitudinal data with nonrandom dropout and informative censoring. Jaffa MA; Gebregziabher M; Jaffa AA Stat Methods Med Res; 2022 Mar; 31(3):451-474. PubMed ID: 34806502 [TBL] [Abstract][Full Text] [Related]
6. A marginalized two-part model for longitudinal semicontinuous data. Smith VA; Neelon B; Preisser JS; Maciejewski ML Stat Methods Med Res; 2017 Aug; 26(4):1949-1968. PubMed ID: 26156962 [TBL] [Abstract][Full Text] [Related]
7. A marginalized two-part model for semicontinuous data. Smith VA; Preisser JS; Neelon B; Maciejewski ML Stat Med; 2014 Dec; 33(28):4891-903. PubMed ID: 25043491 [TBL] [Abstract][Full Text] [Related]
8. A marginalized two-part model with heterogeneous variance for semicontinuous data. Smith VA; Preisser JS Stat Methods Med Res; 2019 May; 28(5):1412-1426. PubMed ID: 29451088 [TBL] [Abstract][Full Text] [Related]
9. A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. Rondeau V; Pignon JP; Michiels S; Stat Methods Med Res; 2015 Dec; 24(6):711-29. PubMed ID: 22025414 [TBL] [Abstract][Full Text] [Related]
10. Nonparametric Bayesian functional two-part random effects model for longitudinal semicontinuous data analysis. Park J; Choi T; Chung Y Biom J; 2021 Apr; 63(4):787-805. PubMed ID: 33554393 [TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
12. Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial. Król A; Ferrer L; Pignon JP; Proust-Lima C; Ducreux M; Bouché O; Michiels S; Rondeau V Biometrics; 2016 Sep; 72(3):907-16. PubMed ID: 26890381 [TBL] [Abstract][Full Text] [Related]
13. Modeling biomarker variability in joint analysis of longitudinal and time-to-event data. Wang C; Shen J; Charalambous C; Pan J Biostatistics; 2024 Apr; 25(2):577-596. PubMed ID: 37230468 [TBL] [Abstract][Full Text] [Related]
14. A two-part joint model for the analysis of survival and longitudinal binary data with excess zeros. Rizopoulos D; Verbeke G; Lesaffre E; Vanrenterghem Y Biometrics; 2008 Jun; 64(2):611-9. PubMed ID: 17725808 [TBL] [Abstract][Full Text] [Related]
15. A likelihood-based two-part marginal model for longitudinal semicontinuous data. Su L; Tom BD; Farewell VT Stat Methods Med Res; 2015 Apr; 24(2):194-205. PubMed ID: 21873302 [TBL] [Abstract][Full Text] [Related]
17. Comparing statistical methods in assessing the prognostic effect of biomarker variability on time-to-event clinical outcomes. Gao F; Luo J; Liu J; Wan F; Wang G; Gordon M; Xiong C BMC Med Res Methodol; 2022 Jul; 22(1):201. PubMed ID: 35869438 [TBL] [Abstract][Full Text] [Related]
18. Bias in 2-part mixed models for longitudinal semicontinuous data. Su L; Tom BD; Farewell VT Biostatistics; 2009 Apr; 10(2):374-89. PubMed ID: 19136448 [TBL] [Abstract][Full Text] [Related]
19. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102 [TBL] [Abstract][Full Text] [Related]
20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA; Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]